Recent Developments of Small Molecule PI3K/mTOR Dual Inhibitors

Author(s): Yan-Na Liu, Ren-Zhong Wan, Zhao-Peng Liu

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 13 , Issue 14 , 2013

Become EABM
Become Reviewer


The phosphoinositide 3-kinases (PI3Ks) are lipid kinases that play a central role in control of cell growth, proliferation, migration, survival and angiogenesis, and drive the progression of tumors by activating phosphoinositidedependent kinase, protein kinase B (Akt) and the mammalian target of rapamycin (mTOR). The PI3K/Akt/mTOR pathway has been shown to play an important role in cancer and has become an important target for anticancer drug development. An interest in targeting two important points along this critical signaling pathway has spurred the development of dual PI3K/mTOR inhibitors that could both prevent cancer cell proliferation and induce programmed cell death (apoptosis) by fully suppressing Akt activation. This review summarizes the developments of a diversity of small molecule dual PI3K/mTOR inhibitors in recent 10 years, with an emphasis on their structural features, the relevant biological activities, and the structure-activity relationships (SARs).

Keywords: Anticancer, anticancer agents, cancer, dual PI3K/mTOR kinase inhibitors, kinase inhibitors, PI3K, PI3K, PI3K/Akt/mTOR, PI3K signaling pathway, mTOR, structure-activity relationships, SARs.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 10 December, 2013
Page: [2047 - 2059]
Pages: 13
DOI: 10.2174/13895575113136660105
Price: $65

Article Metrics

PDF: 34